SMi Group are thrilled to present the 8th annual conference in the industry leading series, Advances in Cell Based Assays, taking place on 10th and 11th November 2015 in Central London, UK.
Due to improvements in detection technology and sensitivity in drug screening, recent reports predict the cell based assays market to reach $4.7 billion by 2016. With a fresh new agenda for 2015, Advances in Cell Based Assays arrives at the perfect time to expand scientific horizons in key topics such as drug toxicity testing, live imaging, 3D modelling, phenotype screening, formulation in assay development, plus much more!
We have worked closely with a leading panel of experts such as AstraZeneca, GSK, Pfizer and Johnson and Johnson, to create a packed programme that has been tailored for an audience of professionals working in regenerative medicine using 3D cell based assays and high-throughput technologies.
Due to improvements in detection technology and sensitivity in drug screening, recent reports predict the cell based assays market to reach $4.7 billion by 2016. With a fresh new agenda for 2015, Advances in Cell Based Assays arrives at the perfect time to expand scientific horizons in key topics such as drug toxicity testing, live imaging, 3D modelling, phenotype screening, formulation in assay development, plus much more!
We have worked closely with a leading panel of experts such as AstraZeneca, GSK, Pfizer and Johnson and Johnson, to create a packed programme that has been tailored for an audience of professionals working in regenerative medicine using 3D cell based assays and high-throughput technologies.
